Home > Oncology > ESMO 2020 > Genitourinary Cancers > New treatment option for patients with mCRPC

New treatment option for patients with mCRPC

ESMO 2020
Metastatic castration-resistant prostate cancer (mCRPC) patients with PTEN loss or BRCA1, BRCA2, or ATM mutations all benefit from targeted therapy. In addition, HLE BiTE® immune therapy is a promising option for all patients with mCRPC. About 40%-50% of mCRPC tumours show loss of the AKT phosphatase PTEN, which leads to hyperactivation of the oncogenic PI3K/AKT signalling pathway. In addition, it has been demonstrated that, due to reciprocal cross talk, blockade of the androgen receptor (AR)-activated pathway activates the PI3K/AKT signalling pathway, enabling prostate cancer cell survival [1]. Therefore, PTEN loss in mCRPC is associated with worse prognosis and reduced benefit of AR blockade. In the randomised phase 3 IPATential 150 trial; 1,101 treatment-naïve patients with asymptomatic or mildly symptomatic mCRPC were 1:1 randomised to receive ipatasertib (400 mg daily) plus abiraterone (1,000 mg daily) and prednisone...

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on